drugset / Trial / NCT02972450
An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection
Phase 1/2
Terminated
1 enrolled
ANRS, Emerging Infectious Diseases
Centre Hospitalier Universitaire Vaudois · collabEuropean Commission · collabEuropean Georges Pompidou Hospital · collabFIT Biotech Ltd. · collabFred Hutchinson Cancer Center · collabHenri Mondor University Hospital · collabImperial College London · collabInstitut d'Investigacions Biomèdiques August Pi i Sunyer · collabIstituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS · collabMedical Research Council · collabSaint-Louis Hospital, Paris, France · collabSwiss Government · collabUniversity College, London · collabUniversitätsklinikum Hamburg-Eppendorf · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
EVHA T01 is an international, phase I/II, multicentre, multi-stage, double-blind study that will evaluate at least three experimental arms compared to placebo control in HIV-1 infected participants to see if one or more has a clinically relevant impact on the control of viral replication.
Timeline
- Start
- 2019-02-20
- Primary completion
- 2019-07-11
- Completion
- 2019-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GTU-MultiHIV B-clade | Vaccine | 2 mg | Intramuscular |
| Subject | MVA HIV-B | Vaccine | 0.5 ml | Intramuscular |
| Subject | Vedolizumab | Monoclonal antibody | 300 mg | Intravenous |